◎ Sugi Atlas

Atlas / Drug / Denileukin Diftitox

Denileukin Diftitox

drug
On this page

Also known as DAB(SUB 389)IL2DAB-389IL2DAB389 IL2DAB389IL2DenileukinDenileukin diftitox-cxdlDenileukina diftitoxDenileukine diftitoxE-7272E-7777E7272E7777LY-335348LY335348LymphirOntakDENILEUKINE-DIFITOX

Summary

Denileukin Diftitox (CHEMBL1201550) is an approved protein (ATC L01XX29); indicated across 23 conditions including neoplasm and primary cutaneous t-cell non-hodgkin lymphoma.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: L01XX29
  • Indications: 23 conditions
  • Clinical trials: 37

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201550
NameDenileukin Diftitox
TypeProtein
Max phase4
ATCL01XX29

Also known as: DAB(SUB 389)IL2, DAB-389IL2, DAB389 IL2, DAB389IL2, Denileukin, Denileukin diftitox, Denileukin diftitox-cxdl, Denileukina diftitox, Denileukine diftitox, E-7272, E-7777, E7272

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

23 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
primary cutaneous T-cell non-Hodgkin lymphoma4MONDO:0000607EFO:0002913
lymphoma3MONDO:0005062EFO:0000574
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
melanoma2MONDO:0005105EFO:0000756
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
acute myeloid leukemia2MONDO:0018874EFO:0000222
leukemia2MONDO:0005059EFO:0000565
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
fallopian tube carcinoma2MONDO:0006206EFO:1000251
peritoneal neoplasm2MONDO:0006901MONDO:0002087
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
ovarian cancer2MONDO:0008170MONDO:0008170
graft versus host disease2MONDO:0013730MONDO:0013730
cutaneous melanoma2MONDO:0005012EFO:0000389
ovarian carcinoma2MONDO:0005140EFO:0001075
plasma cell myeloma1MONDO:0009693EFO:0001378
male breast carcinoma1MONDO:0005628EFO:0006861
endometrioid adenocarcinoma1MONDO:0005026EFO:0000466
ovarian serous cystadenocarcinoma1MONDO:0006046EFO:1000043
kidney cancer0MONDO:0002367MONDO:0002367

Clinical trials

Total trials: 37.

Phase distribution

PhaseTrials
PHASE222
PHASE15
PHASE1/PHASE24
PHASE42
PHASE32
EARLY_PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00050999PHASE4COMPLETEDStudy of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
NCT00051012PHASE4COMPLETEDStudy of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
NCT01355783PHASE3WITHDRAWNA Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
NCT01871727PHASE3COMPLETEDA Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
NCT05200559PHASE1/PHASE2ACTIVE_NOT_RECRUITINGT-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT00003615PHASE2COMPLETEDDenileukin Diftitox in Treating Patients With Non-Hodgkin’s Lymphoma
NCT00006345PHASE2COMPLETEDDexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
NCT00026429PHASE2UNKNOWNDenileukin Diftitox in Treating Patients With Non-Hodgkin’s Lymphoma
NCT00051025PHASE2COMPLETEDPhase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin’s Lymphoma (NHL)
NCT00055146PHASE2COMPLETEDStudy of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
NCT00082914PHASE2COMPLETEDDenileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
NCT00082940PHASE2COMPLETEDDenileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00138164PHASE2COMPLETEDDenileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00211185PHASE2COMPLETEDA Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
NCT00224874PHASE2COMPLETEDTreatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
NCT00299689PHASE2COMPLETEDPhase II Trial of Ontak With Metastatic Melanoma
NCT00337987PHASE2COMPLETEDA Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
NCT00425672PHASE1/PHASE2COMPLETEDONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
NCT00460109PHASE2COMPLETEDRituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin’s Lymphoma
NCT00515528PHASE2TERMINATEDVaccination Plus Ontak in Patients With Metastatic Melanoma
NCT00632827PHASE2TERMINATEDTreatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
NCT00726037PHASE2TERMINATEDA Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
NCT00801918PHASE2WITHDRAWNDenileukine Diftitox for Relapsed ALCL
NCT00880360PHASE2COMPLETEDA Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
NCT00945269PHASE1/PHASE2TERMINATEDTherapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
NCT01106950PHASE2TERMINATEDHaploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
NCT01127451PHASE2COMPLETEDStudy of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
NCT01773889PHASE2TERMINATEDA Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
NCT02676778PHASE2COMPLETEDStudy of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
NCT04855253PHASE1/PHASE2SUSPENDEDPh I/II Study of E7777 Prior to CAR-T for R/R LBCL
NCT00128622PHASE1COMPLETEDDenileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00224354PHASE1WITHDRAWNLymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
NCT00228358PHASE1COMPLETEDCyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient’s Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
NCT00357448PHASE1COMPLETEDDenileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
NCT01401530PHASE1COMPLETEDE7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
NCT00278369EARLY_PHASE1COMPLETEDPilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
NCT00513188Not specifiedWITHDRAWNCombination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem